Wild type p53 reactivation: From lab bench to clinic
- 12 April 2014
- journal article
- review article
- Published by Wiley in FEBS Letters
- Vol. 588 (16) , 2628-2638
Abstract
The p53 tumor suppressor is the most frequently inactivated gene in cancer. Several mouse models have demonstrated that the reconstitution of the p53 function suppresses the growth of established tumors. These facts, taken together, promote the idea of p53 reactivation as a strategy to combat cancer. This review will focus on recent advances in the development of small molecules which restore the function of wild type p53 by blocking its inhibitors Mdm2 and MdmX or their upstream regulators and discuss the impact of different p53 functions for tumor prevention and tumor eradication. Finally, the recent progress in p53 research will be analyzed concerning the role of p53 cofactors and cellular environment in the biological response upon p53 reactivation and how this can be applied in clinic.Keywords
Funding Information
- Swedish Research Council
- Swedish Cancer Society
This publication has 150 references indexed in Scilit:
- Tumor Suppression in the Absence of p53-Mediated Cell-Cycle Arrest, Apoptosis, and SenescenceCell, 2012
- p53-Mediated Senescence Impairs the Apoptotic Response to Chemotherapy and Clinical Outcome in Breast CancerCancer Cell, 2012
- A small molecule Inauhzin inhibits SIRT1 activity and suppresses tumour growth through activation of p53EMBO Molecular Medicine, 2012
- Distinct p53 Transcriptional Programs Dictate Acute DNA-Damage Responses and Tumor SuppressionCell, 2011
- Cellular Metabolic Stress: Considering How Cells Respond to Nutrient ExcessMolecular Cell, 2010
- A Large Intergenic Noncoding RNA Induced by p53 Mediates Global Gene Repression in the p53 ResponseCell, 2010
- Principles of Cancer Therapy: Oncogene and Non-oncogene AddictionCell, 2009
- Mdm2 Regulates p53 mRNA Translation through Inhibitory Interactions with Ribosomal Protein L26Molecular Cell, 2008
- SnapShot: p53 Posttranslational ModificationsCell, 2008
- Discovery, In Vivo Activity, and Mechanism of Action of a Small-Molecule p53 ActivatorCancer Cell, 2008